XClose

EMINENT CONSORTIUM

Menu

Programme outputs

Networking, Publications and other outputs

Networking

The EMINENT network held a highly successful Science Day in January 2020 at GSK in Stevenage. A symposium with overview of the network progress to date, of current and past projects, and presentations from GSK on their new research structure was followed by round table discussions on key questions in experimental medicine research 

Key Publications

  • Samanta R, Dunning J, Taylor A, Bayliffe A, Chambers R, Chilvers ER, Openshaw P, Summers C. Identification of novel mechanistically distinct endotypes of pandemic influenza-associated acute respiratory failure. https://doi.org/10.1101/2020.07.12.20150474
  • Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.Mehta P, Porter JC, Manson JJ, Isaacs JD, Openshaw PJM, McInnes IM, Summers C, Chambers RC. Lancet Respir Med 2020; S2213-2600(20)30267-8
  • Otilimab in patients with severe coronavirus-related lung disease (OSCAR) [UPH]. GSK sponsored Phase III RCT (CI Summers).  EudraCT: 2020-001759-42.

Other outputs

COMBIVAS

Poster presentation

A randomised, double blind, controlled, mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis (COMBIVAS): study protocol

Mark McClure, Seerapani Gopaluni, Kim Mynard, Maria King, James Wason, Antonella Napolitano Rosen, Robert Henderson, Caroline Savage, Charles Pusey, Alan Salama, David Jayne, Rachel Jones and on behalf of the COMBIVAS investigators

International Vasculitis and ANCA workshop, Philadelphia April 2019

Journal publications

Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.

McClure ME, Wason J, Gopaluni S, Tieu J, Smith RM, Jayne DR, Jones RB.

J Clin Rheumatol. 2019 Mar 20. PMID: 30896460

B cell therapy in ANCA-associated vasculitis: current and emerging treatment options.

McClure M1, Gopaluni S1, Jayne D2, Jones R1.

Nat Rev Rheumatol. 2018 Oct;14(10):580-591. PMID: 30108367

INFLAMMAGE

Presentations:

Preliminary findings from the elderly RSV challenge pilot study were presented as a poster at the RSVVW meeting in November 2019 by Stephanie Ascough. This is the foremost international RSV vaccines meeting and was well attended by both academic and industry stakeholders. The work was also highlighted at the meeting in Peter Openshaw’s plenary talk. Dissemination of these findings enabled fruitful discussions with potential industry collaborators with an interest in accessing the model.

Additionally, these findings fed into a successful recent EC IMI grant application on accelerating vaccine development, with the subtopic led by Dr Chiu due to incorporate the model to enable more accurate prediction of vaccine efficacy in the older adult population.

Investigating Oncostatin M as a Mediator of Seronegative Inflammatory Arthritis.

Poster presentation at Newcastle University Institute of Cellular Medicine (ICM) research event.

Poster presentation at the Immunology North East AGM (June 2019). Furthermore, data gathered in this OSM project was communicated via an oral presentation at the North Yorkshire Rheumatology meeting (September 2019). Dr Arthur Pratt

Epigenetic Modifications in Dupuytren’s Disease

Attenuation of Dupuytren’s fibrosis via targeting of the STAT1 modulated IL-13Ra1 response. Science Advances 2020. Moeed Akbar, Emma Garcia-Melchor, Sabarinadh Chilaka, Kevin J. Little, Shatakshi Sood,James H. Reilly, Foo Y. Liew, Iain B. McInnes, Neal L. Millar.

Novel combination therapy for RA: efficacy of anti-CD3 antibody enhanced by p38 inhibitor

Oral presentation: Anti-CD3 and p38 inhibition as a potential novel combination therapy acting to boost CD8 regulatory T cells whilst minimising inflammatory cytokine release in rheumatoid arthritis. Anna Zarafov and Michael Ehrenstein

BSI 2019 meeting Liverpool, Dec 2-5 2019

 

EMINENT-related project outputs:

Induction of human allergen-specific immune regulation following treatment with a combination of Toll-Like Receptor (TLR) 7 agonist with allergen: an in vitro proof of concept study. 

Abstract presentation titled:

 “Effects of Toll-Like Receptor 7 on Dendritic cells and B cells in inducing Tolerogenic Responses during Allergic Inflammation: A Proof Of Concept Study” based on my work with the GSK2974932 tool compound provided through EMINENT. 

EAACI Digital Congress 2020 between the 6th-8th June, and the abstract will be published in the Journal ‘Allergy’.

Max Kirtland1,2, Dr Gemma Vila-Nadal1, Dr Daphne Tsitoura3, Professor Stephen Durham1,2 and Dr Mohamed Shamji1,2.

1. Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, United Kingdom

2. NIHR Biomedical Research Centre, Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, United Kingdom

3. Imperial College London, London, United Kingdom